People with cystic fibrosis are living longer with an ever-growing number entering the geriatric age group.

The implementation of center-based care and the widespread use of CFTR modulators has contributed to the increased life expectancy, necessitating a renewed focus on diseases traditionally associated with aging and not experienced by this patient population.

Recommendations for screening for chronic conditions, such as diabetes and bone disease, among others, differ in this population, and there are additional considerations for drug–drug interactions related to CFTR modulators and other chronic CF-related therapies.